Routine
Notice
Added
Elafibranor treats Primary Biliary Cholangitis, Genfit patent
Detected
March 31st, 2026
Summary
Elafibranor treats Primary Biliary Cholangitis, Genfit patent
Source document (simplified)
Compositions and methods for the treatment of primary biliary cholangitis
Grant US12589086B2 Kind: B2 Mar 31, 2026
Assignee
Genfit
Inventors
Pascal Birman, Alice Roudot, David Magrez, Benoit Noel
Abstract
The invention relates to a pharmaceutical composition comprising elafibranor or a pharmaceutically acceptable salt thereof, for use to treat primary biliary cholangitis (PBC) in a subject intolerant to ursodeoxycholic acid (UDCA).
CPC Classifications
A61K 31/192 A61P 1/16
Filing Date
2021-08-25
Application No.
18017591
Claims
9
Related changes
Source
Analysis generated by AI. Source diff and links are from the original.
Classification
Browse Categories
Agriculture & Food Safety
63
AI Regulation
3
Banking & Finance
266
Consumer & Competition
1
Consumer Protection
44
Courts & Legal
360
Data Privacy & Cybersecurity
74
Defense & National Security
52
Education
20
Energy
107
Environment
85
Government & Legislation
285
Healthcare
136
Housing
16
Immigration
9
Insurance
58
Labor & Employment
114
Legal & Courts
1
Pharma & Drug Safety
103
Securities & Markets
104
Tax
65
Tax & Revenue
1
Telecom & Technology
47
Trade & Sanctions
124
Transportation
57
Get Pharma & Drug Safety alerts
Weekly digest. AI-summarized, no noise.
Free. Unsubscribe anytime.
Get alerts for this source
We'll email you when ChangeBridge: Patent Grants - Therapeutics (A61P) publishes new changes.